Related Experiment Video
Updated: May 5, 2026

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
Published on: December 8, 2023
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in Japan: changes in practice patterns and
Masamitsu Yanada1, Yoshimitsu Shimomura2, Satoshi Yamasaki3
1Department of Hematology and Oncology, Nagoya City University East Medical Center, Nagoya, 464-8547, Japan. myanada@med.nagoya-cu.ac.jp.
This study examined changes in practice patterns and outcomes of allogeneic hematopoietic cell transplantation (HCT) over the past 20 years. Data were analyzed from a Japanese nationwide registry of consecutive adult patients with acute myeloid leukemia who underwent allogeneic HCT between 2001 and 2020. The study population included 17,553 patients, of whom 6653 underwent allogeneic HCT in 2001-2010 and 10,900 in 2011-2020. Patients in the later period were older, were more likely to be in first complete remission, and more frequently received umbilical cord blood transplantation. After adjusting for major covariates, the 2011-2020 cohort had lower risks of overall mortality (hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.80-0.89; P < 0.001), relapse (HR, 0.88; 95% CI, 0.83-0.95; P < 0.001), and non-relapse mortality (NRM; HR, 0.88; 95% CI, 0.81-0.95; P < 0.001). Subgroup analyses revealed improvements in overall survival (OS) regardless of age and disease status. The study found significant changes in allogeneic HCT practice in Japan and showed that the dual decrease in the risks of relapse and NRM contributed to the OS improvement, highlighting the substantial progress in this field over the past two decades.
This study examined changes in practice patterns and outcomes of allogeneic hematopoietic cell transplantation (HCT) over the past 20 years. Data were analyzed from a Japanese nationwide registry of consecutive adult patients with acute myeloid leukemia who underwent allogeneic HCT between 2001 and 2020. The study population included 17,553 patients, of whom 6653 underwent allogeneic HCT in 2001-2010 and 10,900 in 2011-2020. Patients in the later period were older, were more likely to be in first complete remission, and more frequently received umbilical cord blood transplantation. After adjusting for major covariates, the 2011-2020 cohort had lower risks of overall mortality (hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.80-0.89; P < 0.001), relapse (HR, 0.88; 95% CI, 0.83-0.95; P < 0.001), and non-relapse mortality (NRM; HR, 0.88; 95% CI, 0.81-0.95; P < 0.001). Subgroup analyses revealed improvements in overall survival (OS) regardless of age and disease status. The study found significant changes in allogeneic HCT practice in Japan and showed that the dual decrease in the risks of relapse and NRM contributed to the OS improvement, highlighting the substantial progress in this field over the past two decades.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Regulation of Hematopoietic Stem Cells
Hematopoiesis
Differentiation of Common Myeloid Progenitor Cells
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

